Overview
CellMosaic® is a Massachusetts-based bioconjugation technology company founded in 2008 by Dr. Yumei Huang. We develop innovative, high-quality bioconjugation solutions for research, diagnostic, and therapeutic applications.
CellMosaic has developed more than 400 proprietary Advanced Conjugation Processes supported by validated manufacturing and quality-control systems. As of February 2026, we had completed more than 700 custom projects and produced more than 500 unique conjugates. Our products have been sold to more than 450 organizations in over 33 countries.
Our proprietary AqueaTether® (AqT®) Technologies use sugar alcohol-based linkers to improve the labeling and conjugation of hydrophobic compounds. The platform supports next-generation kits, reagents, and therapeutic development, including antibody–drug conjugates (ADCs).
Other proprietary platforms include oxLink™ and sxLink™ technologies for studying protein–protein interactions and NeIon™ Technologies for detecting trace analytes by mass spectrometry. Our technology development has been supported in part by a U.S. Department of Defense Breast Cancer Research Program Breakthrough Award and NIH SBIR funding.
CellMosaic operates through four complementary business units:
1. Reagents and Kits: Premade bioconjugates, modified molecules, reagents, and kits for preparing bioconjugates in-house.
2. R&D Bioconjugation Services: Custom services and standardized services through our Routine Synthesis™ platform.
3. CDMO Services: Process development, scale-up, and GLP/GMP manufacturing of therapeutic and diagnostic bioconjugates using established linker technologies.
4. AqT® ADC Development and Manufacturing: Next-generation ADC development and manufacturing using proprietary AqT® linkers.
Together, these businesses provide an integrated workflow from early discovery through commercialization.
Advancing Bioconjugation. From Discovery to Commercialization.